SEC Form 6-K Summary
Issuer: I-MAB, a foreign private issuer headquartered in Shanghai, China. The provided metadata identifies Novabridge Biosciences, but the filing itself identifies I-MAB as the registrant.
Reporting period: Month of February 2021; furnished February 8, 2021. Commission File Number 001-39173. I-MAB reports, or intends to report, annual information on Form 20-F.
Business Context and Filing Purpose
The filing furnishes Exhibit 1.1, a form of underwriting agreement. The exhibit is incorporated by reference into I-MAB’s Form F-3 registration statement, File No. 333-252793, to the extent it is not superseded by subsequently filed or furnished documents.
Financial Metrics
The filing does not provide financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not describe operating results, financial changes, acquisitions, financing proceeds, or other changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No management guidance, business outlook, risk-factor update, contingency, or unusual accounting or operating item is provided in the filing text. The principal disclosed action is the filing and incorporation by reference of the underwriting agreement exhibit.
Important Facts to Verify
- Confirm the issuer identity, because the filing names I-MAB while the request metadata names Novabridge Biosciences.
- Review Exhibit 1.1 for the terms, parties, obligations, and conditions of the underwriting agreement.
- Review the referenced Form F-3 registration statement for the securities offering, intended use of proceeds, and related risk factors.
- Check subsequent SEC filings for amendments or documents that supersede the incorporated underwriting agreement.